Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.
Shuichi Mitsunaga
No relevant relationships to disclose
Masafumi Ikeda
No relevant relationships to disclose
Hideki Ueno
No relevant relationships to disclose
Kohei Nakachi
No relevant relationships to disclose
Chigusa Morizane
No relevant relationships to disclose
Shunsuke Kondo
No relevant relationships to disclose
Satoshi Shimizu
No relevant relationships to disclose
Yasushi Kojima
No relevant relationships to disclose
Takuya Suzuki
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Toshiyuki Tamai
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
James P. O'Brien
Employment or Leadership Position - Eisai
Takuji Okusaka
Honoraria - Eisai